Hjem › Mantelcellelymfom › Ohio
Kliniske studier for Mantelcellelymfom i Ohio
16 studier for Mantelcellelymfom søker deltakere på steder i Ohio.
Byer i Ohio
Offisiell studietekst (engelsk)
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 3
Alder 60 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05976763A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- University Hospitals, Cleveland
- Cleveland Clinic Foundation, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
- og 1 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06742996A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Cleveland Clinic, Cleveland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07101328Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
- Case Western Reserve University, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07003295Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07225439A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Columbus
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06564038Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
RekruttererFase 1/2
Alder 13 til 90 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06533579DALY II USA/ MB-CART2019.1 for DLBCL
- The Ohio State University Wexner Medical Center James Cancer, Columbus
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. jul. 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. jul. 2026 · NCT05131022Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- The Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. apr. 2026 · NCT03523975The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
RekruttererFase 1/2
Alder 12 til 95 · Alle kjønn · Oppdatert 15. apr. 2026 · NCT04329728Study of SGR-1505 in Mature B-Cell Neoplasms
- Gabrail Cancer & Research Center, Canton
- The Ohio State University - The James Cancer Hospital, Columbus
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 13. feb. 2026 · NCT05544019Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- University of Cincinnati, Cincinnati
- Ohio State University, Columbus
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 13. feb. 2026 · NCT04775745AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Taylor Cancer Research Center, Maumee
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. des. 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University Hospitals Cleveland Medical Center, Cleveland
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2025 · NCT05780034Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.